Morgan Stanley maintains Aramark at Equal-Weight, lowers price target to $61 from $63

Morgan Stanley kept Aramark at Equal-Weight, cutting its price target to $61 from $63, a 3.2% reduction. The new target suggests a 10.2% upside from the Nov 16 close of $55.37.

Original reporting
Published Nov 17, 2026, 11:49 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 11:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Morgan Stanley maintains Aramark at Equal-Weight, lowers price target to $61 from $63 — source image
Decision brief

The 30-second read

$ARMKNeutralLow
01

Why it matters

A lower price target can influence short-term positioning and expectations, but unchanged rating and lack of new company-specific fundamentals suggest limited immediate repricing.

02

Market read

This is a valuation-anchor update for Aramark rather than a fundamental catalyst.

03

What to watch

Traders may already be anchored to prior target levels; without new earnings or guidance, the market may discount the change unless it coincides with other catalysts not mentioned here.

Relevance 4/10Novelty 4/10Timing: as of the analyst note publication date, for positioning around target changes

Background

The piece is an analyst action: Morgan Stanley reiterates Aramark’s Equal-Weight rating and lowers its price target.

Company-level read

Ticker impact

$ARMKNeutralMedium confidence
Context

Morgan Stanley maintained Aramark at Equal-Weight and cut its price target to $61 from $63, resetting the stock’s analyst valuation anchor.

Expected impact

Likely mild downside or capped upside as traders adjust to the lower target while the Equal-Weight stance limits aggressive selling.

Evidence & confidence

The article provides a specific, time-relevant analyst price-target reduction (from $63 to $61) but no new operational or earnings catalyst, so impact should be modest.

Market effects

Limited spillover to the broader contract dining/facilities services peer group because this is a single-name target cut without new sector data.

No clear regional market linkage from the provided text.

Minimal global relevance; this is a US-listed single-company analyst update.

Counterpoint

Because the rating is unchanged (Equal-Weight), the target cut may be viewed as incremental and not a strong signal of deteriorating fundamentals.

Key entities

  • Aramark

    US operator covered by Morgan Stanley; subject of the maintained Equal-Weight rating and lowered $61 price target.

  • Morgan Stanley

    Maintained the rating and reduced the price target, providing the new valuation anchor.

Related articles

$ARMKMed

Aramark Q4 2026 Earnings Call Summary

Aramark reported record annualized gross new client wins of $1.9 billion, a 97% client retention rate, and launched Aramark Nexus. The company reduced its leverage ratio to 2.7x, enabling a $1 billion share repurchase program and a 17% dividend increase. For fiscal 2027, Aramark projects $500 million in revenue from Nexus, 9-10% organic revenue growth, and 15-19% adjusted operating income growth. Management highlighted supply chain efficiencies and mitigating inflation impacts.

$ARMKMed

Aramark (ARMK) Q4 2026 Earnings Call Transcript

Aramark (ARMK) reported Q4 2026 revenue of $20.1B, up 10% YoY, with U.S. and international organic growth of 8% and 12%, respectively. Adjusted EPS grew 21% on a constant currency basis. The company announced a $1B share repurchase program and a 17% dividend increase. Key segments like Collegiate Hospitality and Healthcare Plus drove growth. Aramark Nexus contributed 1% to organic revenue growth, scaling premium hospitality services.

$ARMKHigh

Why is Aramark stock sliding today?

Aramark (ARMK) shares fell 4.7% pre-market after reporting Q4 2026 results that missed estimates, with adjusted EPS at $0.71 vs. $0.75 and revenue at $5.29B vs. $5.30B. The company's fiscal 2027 guidance also fell short of expectations. Despite a 25% YoY EPS increase and 4.8% revenue growth, the stock dropped due to broader market pressures and the earnings miss.